New drug development
We plan to develop human and animal stem cell therapy using the FreSHtracer™ platform and license them out.
High-purity stem cell separation
Separation of stem cells from various donors
Selection of customized stem cell culture media
Culture high-quality stem cells
Selection of disease-targeted stem cells
Stem cells with enhanced anti-inflammatory and immunosuppressive functions
- Immune-modulatory T, Treg, NK, B cell
- Anti-apoptotic STC-1, VEGF, HGF, IGF-4
- Secrete growth factor SCF, M-SCF, KGF, LIF
- Extracellular matrix remodeling Type II collagen
- Homing PDGF, IGF-1, chemokine
Application of the self-developed quality control platform
Production of personalized stem cell therapy
- Intractable asthma
- Degenerative arthritis
- Idiopathic pulmonary fibrosis
- Graft-versus-host disease
- Multiple sclerosis
- Animal disease
Collaboration in Korea and overseas
License Out
Clinical phase 1/2a
Technology transfer
Global Big Pharma
Joint large scale clinical trials
Reinvestment in back-up pipelines (expanded indications of cell therapy)
